GT Biopharma, Inc. (GTBP)
USD 2.05
(-21.46%)
USD 2.05
(-21.46%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 13.57 Million USD | -36.13% |
| 2022 | 21.25 Million USD | -63.04% |
| 2021 | 57.51 Million USD | 750.31% |
| 2020 | 6.76 Million USD | -40.96% |
| 2019 | 11.45 Million USD | -46.85% |
| 2018 | 21.55 Million USD | -84.1% |
| 2017 | 135.57 Million USD | 1346.23% |
| 2016 | 9.37 Million USD | 4.69% |
| 2015 | 8.95 Million USD | 273.08% |
| 2014 | 2.4 Million USD | 156.68% |
| 2013 | 935 Thousand USD | -75.15% |
| 2012 | 3.76 Million USD | -3.69% |
| 2011 | 3.9 Million USD | 59.89% |
| 2010 | 2.44 Million USD | 111.7% |
| 2009 | 1.15 Million USD | -20.14% |
| 2008 | 1.44 Million USD | -62.99% |
| 2007 | 3.9 Million USD | -27.19% |
| 2006 | 5.36 Million USD | 88.74% |
| 2005 | 2.84 Million USD | 25.6% |
| 2004 | 2.26 Million USD | 12.15% |
| 2003 | 2.01 Million USD | 17.2% |
| 2002 | 1.72 Million USD | -56.88% |
| 2001 | 3.99 Million USD | -29.36% |
| 2000 | 5.65 Million USD | -13.4% |
| 1999 | 6.52 Million USD | -32.04% |
| 1998 | 9.6 Million USD | 18.52% |
| 1997 | 8.1 Million USD | -10.99% |
| 1996 | 9.1 Million USD | 1.11% |
| 1995 | 9 Million USD | 125.0% |
| 1994 | 4 Million USD | 14.29% |
| 1993 | 3.5 Million USD | 66.67% |
| 1992 | 2.1 Million USD | -4.55% |
| 1991 | 2.2 Million USD | -8.33% |
| 1990 | 2.4 Million USD | -4.0% |
| 1989 | 2.5 Million USD | 19.05% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.9 Million USD | 26.37% |
| 2024 Q1 | 3.09 Million USD | -2.43% |
| 2023 Q4 | 3.16 Million USD | 1.47% |
| 2023 Q2 | 3.62 Million USD | -1.2% |
| 2023 Q1 | 3.66 Million USD | -36.57% |
| 2023 FY | 13.57 Million USD | -36.13% |
| 2023 Q3 | 3.12 Million USD | -13.78% |
| 2022 FY | 21.25 Million USD | -63.04% |
| 2022 Q2 | 3.01 Million USD | -44.62% |
| 2022 Q1 | 5.44 Million USD | -70.06% |
| 2022 Q4 | 5.77 Million USD | -17.73% |
| 2022 Q3 | 7.02 Million USD | 133.01% |
| 2021 Q4 | 18.17 Million USD | 205.31% |
| 2021 Q1 | 29 Million USD | 1223.69% |
| 2021 Q2 | 4.38 Million USD | -84.89% |
| 2021 Q3 | 5.95 Million USD | 35.91% |
| 2021 FY | 57.51 Million USD | 750.31% |
| 2020 Q2 | 1.55 Million USD | 45.61% |
| 2020 FY | 6.76 Million USD | -40.96% |
| 2020 Q1 | 1.07 Million USD | 23.56% |
| 2020 Q4 | 2.19 Million USD | 12.65% |
| 2020 Q3 | 1.94 Million USD | 24.84% |
| 2019 Q2 | 2.27 Million USD | -43.81% |
| 2019 FY | 11.45 Million USD | -46.85% |
| 2019 Q4 | 866 Thousand USD | -79.65% |
| 2019 Q3 | 4.25 Million USD | 86.75% |
| 2019 Q1 | 4.05 Million USD | 31.22% |
| 2018 Q2 | 5.15 Million USD | -27.97% |
| 2018 FY | 21.55 Million USD | -84.1% |
| 2018 Q4 | 3.09 Million USD | -49.71% |
| 2018 Q1 | 7.16 Million USD | 21.54% |
| 2018 Q3 | 6.14 Million USD | 19.18% |
| 2017 Q2 | 1.28 Million USD | -16.45% |
| 2017 Q4 | 5.89 Million USD | -95.36% |
| 2017 FY | 135.57 Million USD | 1346.23% |
| 2017 Q1 | 1.53 Million USD | 87.1% |
| 2017 Q3 | 126.85 Million USD | 9772.06% |
| 2016 Q4 | 822 Thousand USD | -67.51% |
| 2016 Q3 | 2.53 Million USD | 19.28% |
| 2016 Q1 | 3.9 Million USD | 34.15% |
| 2016 Q2 | 2.12 Million USD | -45.63% |
| 2016 FY | 9.37 Million USD | 4.69% |
| 2015 Q3 | 2.77 Million USD | 91.39% |
| 2015 FY | 8.95 Million USD | 273.08% |
| 2015 Q4 | 2.9 Million USD | 4.72% |
| 2015 Q1 | 1.81 Million USD | 10.85% |
| 2015 Q2 | 1.45 Million USD | -20.19% |
| 2014 Q3 | 547 Thousand USD | 388.39% |
| 2014 Q1 | 101 Thousand USD | -59.76% |
| 2014 Q2 | 112 Thousand USD | 10.89% |
| 2014 Q4 | 1.64 Million USD | 199.82% |
| 2014 FY | 2.4 Million USD | 156.68% |
| 2013 Q3 | 200 Thousand USD | 69.49% |
| 2013 FY | 935 Thousand USD | -75.15% |
| 2013 Q4 | 251 Thousand USD | 25.5% |
| 2013 Q2 | 118 Thousand USD | -67.76% |
| 2013 Q1 | 366 Thousand USD | -59.2% |
| 2012 Q2 | 1.03 Million USD | 160.35% |
| 2012 Q1 | 396 Thousand USD | -62.32% |
| 2012 FY | 3.76 Million USD | -3.69% |
| 2012 Q4 | 897 Thousand USD | -37.62% |
| 2012 Q3 | 1.43 Million USD | 39.48% |
| 2011 Q2 | 467 Thousand USD | -74.8% |
| 2011 Q3 | 535 Thousand USD | 14.56% |
| 2011 FY | 3.9 Million USD | 59.89% |
| 2011 Q4 | 1.05 Million USD | 96.45% |
| 2011 Q1 | 1.85 Million USD | 291.75% |
| 2010 Q4 | 473 Thousand USD | -27.68% |
| 2010 Q2 | 386 Thousand USD | -58.49% |
| 2010 Q3 | 654 Thousand USD | 69.43% |
| 2010 FY | 2.44 Million USD | 111.7% |
| 2010 Q1 | 930 Thousand USD | 32.67% |
| 2009 Q1 | 139 Thousand USD | 140.52% |
| 2009 FY | 1.15 Million USD | -20.14% |
| 2009 Q2 | 231 Thousand USD | 66.19% |
| 2009 Q4 | 701 Thousand USD | 734.52% |
| 2009 Q3 | 84 Thousand USD | -63.64% |
| 2008 Q3 | 349 Thousand USD | -20.68% |
| 2008 Q2 | 440 Thousand USD | -55.96% |
| 2008 FY | 1.44 Million USD | -62.99% |
| 2008 Q1 | 999 Thousand USD | -12.75% |
| 2008 Q4 | -343 Thousand USD | -198.28% |
| 2007 Q1 | 1.11 Million USD | -41.68% |
| 2007 Q2 | 635 Thousand USD | -43.0% |
| 2007 Q4 | 1.14 Million USD | 13.37% |
| 2007 FY | 3.9 Million USD | -27.19% |
| 2007 Q3 | 1.01 Million USD | 59.06% |
| 2006 Q2 | 1.01 Million USD | -20.52% |
| 2006 Q4 | 1.91 Million USD | 64.66% |
| 2006 Q1 | 1.27 Million USD | 16.2% |
| 2006 Q3 | 1.16 Million USD | 14.29% |
| 2006 FY | 5.36 Million USD | 88.74% |
| 2005 FY | 2.84 Million USD | 25.6% |
| 2005 Q4 | 1.09 Million USD | 103.9% |
| 2005 Q3 | 539 Thousand USD | -10.91% |
| 2005 Q2 | 605 Thousand USD | 1.17% |
| 2005 Q1 | 598 Thousand USD | 42.38% |
| 2004 Q2 | 698 Thousand USD | 0.29% |
| 2004 FY | 2.26 Million USD | 12.15% |
| 2004 Q4 | 420 Thousand USD | -20.45% |
| 2004 Q3 | 528 Thousand USD | -24.36% |
| 2004 Q1 | 696 Thousand USD | 13.91% |
| 2003 Q3 | 445 Thousand USD | -6.9% |
| 2003 FY | 2.01 Million USD | 17.2% |
| 2003 Q1 | 483 Thousand USD | 37.22% |
| 2003 Q2 | 478 Thousand USD | -1.04% |
| 2003 Q4 | 611 Thousand USD | 37.3% |
| 2002 FY | 1.72 Million USD | -56.88% |
| 2002 Q4 | 352 Thousand USD | -26.82% |
| 2002 Q3 | 481 Thousand USD | 14.25% |
| 2002 Q2 | 421 Thousand USD | -9.85% |
| 2002 Q1 | 467 Thousand USD | -63.54% |
| 2001 Q2 | 1.34 Million USD | -0.81% |
| 2001 FY | 3.99 Million USD | -29.36% |
| 2001 Q4 | 1.28 Million USD | 163.04% |
| 2001 Q1 | 1.35 Million USD | -15.81% |
| 2001 Q3 | 487 Thousand USD | -63.71% |
| 2000 Q2 | 1.2 Million USD | -0.58% |
| 2000 Q1 | 1.21 Million USD | -8.16% |
| 2000 FY | 5.65 Million USD | -13.4% |
| 2000 Q3 | 1.61 Million USD | 33.83% |
| 2000 Q4 | 1.6 Million USD | -0.68% |
| 1999 FY | 6.52 Million USD | -32.04% |
| 1999 Q2 | 2.1 Million USD | 5.0% |
| 1999 Q1 | 2 Million USD | -31.03% |
| 1999 Q3 | 1.2 Million USD | -42.86% |
| 1999 Q4 | 1.32 Million USD | 10.33% |
| 1998 Q1 | 2.3 Million USD | 15.0% |
| 1998 Q2 | 1.9 Million USD | -17.39% |
| 1998 Q3 | 2.7 Million USD | 42.11% |
| 1998 Q4 | 2.9 Million USD | 7.41% |
| 1998 FY | 9.6 Million USD | 18.52% |
| 1997 Q1 | 2.2 Million USD | -4.35% |
| 1997 Q3 | 2.1 Million USD | 16.67% |
| 1997 FY | 8.1 Million USD | -10.99% |
| 1997 Q4 | 2 Million USD | -4.76% |
| 1997 Q2 | 1.8 Million USD | -18.18% |
| 1996 Q4 | 2.3 Million USD | 4.55% |
| 1996 Q1 | 2.3 Million USD | -14.81% |
| 1996 FY | 9.1 Million USD | 1.11% |
| 1996 Q3 | 2.2 Million USD | -8.33% |
| 1996 Q2 | 2.4 Million USD | 4.35% |
| 1995 FY | 9 Million USD | 125.0% |
| 1995 Q4 | 2.7 Million USD | 28.57% |
| 1995 Q3 | 2.1 Million USD | 0.0% |
| 1995 Q2 | 2.1 Million USD | 0.0% |
| 1995 Q1 | 2.1 Million USD | -4.55% |
| 1994 Q3 | 900 Thousand USD | 125.0% |
| 1994 Q4 | 2.2 Million USD | 144.44% |
| 1994 FY | 4 Million USD | 14.29% |
| 1994 Q1 | 500 Thousand USD | -28.57% |
| 1994 Q2 | 400 Thousand USD | -20.0% |
| 1993 Q2 | 1.5 Million USD | 275.0% |
| 1993 Q3 | 900 Thousand USD | -40.0% |
| 1993 Q4 | 700 Thousand USD | -22.22% |
| 1993 FY | 3.5 Million USD | 66.67% |
| 1993 Q1 | 400 Thousand USD | 0.0% |
| 1992 Q4 | 400 Thousand USD | -33.33% |
| 1992 Q1 | 500 Thousand USD | 0.0% |
| 1992 Q2 | 500 Thousand USD | 0.0% |
| 1992 Q3 | 600 Thousand USD | 20.0% |
| 1992 FY | 2.1 Million USD | -4.55% |
| 1991 Q2 | - USD | 0.0% |
| 1991 Q4 | 500 Thousand USD | -16.67% |
| 1991 Q3 | 600 Thousand USD | 0.0% |
| 1991 Q1 | - USD | 100.0% |
| 1991 FY | 2.2 Million USD | -8.33% |
| 1990 Q1 | - USD | 100.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q4 | -4.3 Million USD | 0.0% |
| 1990 FY | 2.4 Million USD | -4.0% |
| 1990 Q2 | - USD | 0.0% |
| 1989 Q2 | - USD | 0.0% |
| 1989 FY | 2.5 Million USD | 19.05% |
| 1989 Q3 | - USD | 0.0% |
| 1989 Q4 | -4.6 Million USD | 0.0% |
| 1989 Q1 | - USD | 100.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | 6.872% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 95.781% |
| IO Biotech, Inc. | 91.44 Million USD | 85.154% |
| VYNE Therapeutics Inc. | 29.68 Million USD | 54.262% |
| Organovo Holdings, Inc. | 14.91 Million USD | 8.978% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | 17.018% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -101.762% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 88.818% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 85.477% |
| Savara Inc. | 15.74 Million USD | 13.776% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 83.324% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 94.772% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | 2.399% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | 5.79% |
| Soligenix, Inc. | 7.79 Million USD | -74.157% |
| Aptose Biosciences Inc. | 52.35 Million USD | 74.07% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | 52.437% |
| Century Therapeutics, Inc. | 56.07 Million USD | 75.788% |
| Eterna Therapeutics Inc. | 19.38 Million USD | 29.959% |
| Precision BioSciences, Inc. | 92.46 Million USD | 85.317% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 97.15% |
| Kura Oncology, Inc. | 165.8 Million USD | 91.812% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -92.412% |
| Dyadic International, Inc. | 9.15 Million USD | -48.328% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 88.144% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 91.397% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 87.394% |
| Autolus Therapeutics plc | 196.72 Million USD | 93.099% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | 38.992% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 88.342% |
| GRI Bio, Inc. | 11.33 Million USD | -19.823% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 89.652% |
| IGM Biosciences, Inc. | 265.59 Million USD | 94.888% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 92.132% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 66.325% |
| Entero Therapeutics, Inc. | 15.74 Million USD | 13.757% |
| Opthea Limited | 191.96 Million USD | 92.928% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 87.374% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 95.076% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 92.69% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 83.9% |
| Surrozen, Inc. | 18.55 Million USD | 26.814% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -166.707% |
| Cingulate Inc. | 22.75 Million USD | 40.349% |
| Ovid Therapeutics Inc. | 59.67 Million USD | 77.249% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 96.636% |
| Acelyrin, Inc. | 422.06 Million USD | 96.783% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 92.379% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | 71.978% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 94.459% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | 55.881% |
| ADMA Biologics, Inc. | 66.58 Million USD | 79.611% |
| PureTech Health plc | 144.59 Million USD | 90.611% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -6.512% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -52.728% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 83.975% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 94.439% |
| Synaptogenix, Inc. | 8.31 Million USD | -63.294% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | 6.924% |
| ChromaDex Corporation | 56.37 Million USD | 75.92% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -101.665% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -53.727% |
| Exelixis, Inc. | 1.58 Billion USD | 99.144% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 93.25% |
| Better Therapeutics, Inc. | 38.26 Million USD | 64.518% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 94.15% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 98.413% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 94.063% |
| Seer, Inc. | 110.49 Million USD | 87.713% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 54.736% |
| LAVA Therapeutics N.V. | 46.54 Million USD | 70.829% |
| Gritstone bio, Inc. | 148.37 Million USD | 90.85% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 80.285% |
| Avid Bioservices, Inc. | 25.99 Million USD | 47.777% |
| Insmed Incorporated | 949.26 Million USD | 98.57% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 47.066% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -2021.25% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 94.656% |
| MediWound Ltd. | 18.86 Million USD | 28.047% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 92.102% |
| Fortress Biotech, Inc. | 200.19 Million USD | 93.219% |
| OmniAb, Inc. | 83.89 Million USD | 83.818% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 94.206% |
| Zai Lab Limited | 547.47 Million USD | 97.52% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 96.595% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 91.462% |
| Veracyte, Inc. | 357.93 Million USD | 96.207% |
| Abeona Therapeutics Inc. | 17.93 Million USD | 24.321% |
| FibroGen, Inc. | 398.11 Million USD | 96.59% |
| Apogee Therapeutics, Inc. | 93 Million USD | 85.403% |
| ContextLogic Inc. | 387 Million USD | 96.492% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -63.193% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -97.098% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | 58.542% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 99.583% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 89.729% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | 47.528% |
| ImmuCell Corporation | 9.61 Million USD | -41.161% |
| Fortrea Holdings Inc. | 457.3 Million USD | 97.031% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | 74.988% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 80.285% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 90.444% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 98.583% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 87.738% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | 52.935% |
| Vaxxinity, Inc. | 56.05 Million USD | 75.779% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 96.847% |
| Gain Therapeutics, Inc. | 22.3 Million USD | 39.144% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -145.455% |
| Marker Therapeutics, Inc. | 17.89 Million USD | 24.125% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | 71.119% |
| Senti Biosciences, Inc. | 94.7 Million USD | 85.665% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | 11.652% |
| Apollomics, Inc. | 54.14 Million USD | 74.924% |
| 89bio, Inc. | 151.2 Million USD | 91.021% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 96.954% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | 30.087% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 89.315% |
| Ardelyx, Inc. | 169.93 Million USD | 92.011% |
| Pluri Inc. | 22.48 Million USD | 39.609% |
| Prothena Corporation plc | 282.4 Million USD | 95.193% |
| Pulmatrix, Inc. | 22.03 Million USD | 38.397% |
| Celularity Inc. | 215.05 Million USD | 93.687% |
| MeiraGTx Holdings plc | 151.07 Million USD | 91.014% |
| Omeros Corporation | 94.75 Million USD | 85.672% |
| Ainos, Inc. | 12.95 Million USD | -4.812% |
| Humacyte, Inc. | 23.49 Million USD | 42.222% |
| Mesoblast Limited | 5.9 Million USD | -130.024% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -300.472% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 84.371% |
| Blueprint Medicines Corporation | 722.86 Million USD | 98.122% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 81.816% |
| Summit Therapeutics Inc. | 87.68 Million USD | 84.517% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | 53.931% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 92.074% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 97.539% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | 81.288% |
| Cytokinetics, Incorporated | 173.61 Million USD | 92.18% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 60.557% |
| Nutriband Inc. | 5.73 Million USD | -136.762% |
| Protara Therapeutics, Inc. | 43.61 Million USD | 68.872% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 98.858% |
| Evogene Ltd. | 27.79 Million USD | 51.148% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 81.697% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -76.49% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 97.79% |
| BioLineRx Ltd. | 50.8 Million USD | 73.277% |
| Atai Life Sciences N.V. | 125.78 Million USD | 89.207% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | 60.17% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 94.635% |
| MediciNova, Inc. | 10.9 Million USD | -24.547% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 89.461% |
| MiMedx Group, Inc. | 229.72 Million USD | 94.09% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 98.965% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 92.895% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 94.096% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | 15.04% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 50.779% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 89.838% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 94.394% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 94.819% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 93.473% |
| Allakos Inc. | 196.05 Million USD | 93.075% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 88.035% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 96.317% |
| BioAtla, Inc. | 129.68 Million USD | 89.532% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 84.013% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | 67.489% |
| Precigen, Inc. | 84.18 Million USD | 83.873% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | 59.268% |
| XOMA Corporation | 46.46 Million USD | 70.781% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 87.788% |
| Incyte Corporation | 1.19 Billion USD | 98.86% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 90.471% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 86.903% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 44.147% |
| CRISPR Therapeutics AG | 463.49 Million USD | 97.071% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 92.147% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | 63.708% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -65.061% |
| UroGen Pharma Ltd. | 138.88 Million USD | 90.225% |
| Sutro Biopharma, Inc. | 243 Million USD | 94.413% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -86.621% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | 47.192% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 89.012% |
| Chimerix, Inc. | 93.38 Million USD | 85.463% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | 74.446% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -175.174% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 93.727% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | 15.405% |
| Portage Biotech Inc. | 18.19 Million USD | 25.402% |
| OncoCyte Corporation | 25.63 Million USD | 47.045% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -122.718% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -77.863% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -18.495% |
| Purple Biotech Ltd. | -22.46 Million USD | 160.426% |
| NextCure, Inc. | 67.63 Million USD | 79.928% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -60.611% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -68.816% |
| Generation Bio Co. | 144.46 Million USD | 90.603% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 92.76% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 91.94% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 28.279% |
| NLS Pharmaceutics AG | 11.8 Million USD | -14.982% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 83.964% |
| Novavax, Inc. | 779.12 Million USD | 98.258% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -149.242% |
| Curis, Inc. | 58.35 Million USD | 76.735% |
| Daré Bioscience, Inc. | 33.6 Million USD | 59.607% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -81.96% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | 13.472% |
| Bicycle Therapeutics plc | 216.92 Million USD | 93.742% |
| BeiGene, Ltd. | 3.28 Billion USD | 99.587% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 31.913% |
| Alector, Inc. | 248.8 Million USD | 94.543% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 91.164% |
| Erasca, Inc. | 141.52 Million USD | 90.407% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | 74.018% |
| Aura Biosciences, Inc. | 84.99 Million USD | 84.027% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 73.219% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | 46.675% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -199.891% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | 81.292% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 99.223% |
| Histogen Inc. | 14.27 Million USD | 4.877% |
| Fortress Biotech, Inc. | 200.19 Million USD | 93.219% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 94.462% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 94.507% |
| Galecto, Inc. | 35.62 Million USD | 61.894% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.849% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 91.911% |
| Molecular Templates, Inc. | 63.09 Million USD | 78.482% |
| PDS Biotechnology Corporation | 43.04 Million USD | 68.461% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 95.711% |
| Amarin Corporation plc | 272.35 Million USD | 95.015% |
| TG Therapeutics, Inc. | 198.47 Million USD | 93.16% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | 52.988% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | 68.729% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 93.477% |
| Onconetix, Inc. | 34.9 Million USD | 61.109% |
| MacroGenics, Inc. | 217.21 Million USD | 93.75% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 86.297% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | 54.144% |
| Adagene Inc. | 41.83 Million USD | 67.546% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 93.824% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 87.755% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | 62.102% |
| SciSparc Ltd. | 9.01 Million USD | -50.66% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -56.827% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | 41.2% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 83.649% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 84.298% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 95.409% |
| Relay Therapeutics, Inc. | 72.15 Million USD | 81.186% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 99.246% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -393.388% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -31.972% |
| 2seventy bio, Inc. | 289.88 Million USD | 95.317% |
| Clene Inc. | 41.07 Million USD | 66.947% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | 75.224% |
| GeoVax Labs, Inc. | 6.02 Million USD | -125.434% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -90.521% |
| Arbutus Biopharma Corporation | 22.54 Million USD | 39.78% |
| Scopus BioPharma Inc. | 11.71 Million USD | -15.887% |
| Absci Corporation | 73.66 Million USD | 81.571% |
| XBiotech Inc. | 37.51 Million USD | 63.807% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 92.027% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | 34.253% |
| Entera Bio Ltd. | 8.86 Million USD | -53.228% |
| Trevena, Inc. | 38.41 Million USD | 64.658% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 93.213% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 90.982% |
| INmune Bio, Inc. | 29.89 Million USD | 54.589% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | 63.04% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 83.018% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 281.207% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 69.606% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -64.879% |
| Jaguar Health, Inc. | 42.01 Million USD | 67.688% |
| Clearside Biomedical, Inc. | 32.71 Million USD | 58.502% |
| NexImmune, Inc. | 28.16 Million USD | 51.803% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | 78.129% |
| Clearmind Medicine Inc. | 8.74 Million USD | -55.308% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | 33.743% |
| Kronos Bio, Inc. | 128.11 Million USD | 89.404% |
| Innoviva, Inc. | 132.15 Million USD | 89.727% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 95.496% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.518% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 83.852% |
| Verastem, Inc. | 92.08 Million USD | 85.257% |
| ProKidney Corp. | 151.52 Million USD | 91.04% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -362.873% |
| Imunon, Inc. | 20.31 Million USD | 33.157% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 86.535% |
| Statera Biopharma, Inc. | 28.82 Million USD | 52.909% |
| ImmunityBio, Inc. | 362.87 Million USD | 96.259% |
| Korro Bio, Inc. | 84.53 Million USD | 83.94% |
| Travere Therapeutics, Inc. | 472 Million USD | 97.124% |
| Kineta, Inc. | 21.15 Million USD | 35.829% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 94.767% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -5.997% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 91.98% |
| Celularity Inc. | 215.05 Million USD | 93.687% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 94.009% |
| CalciMedica, Inc. | 21.81 Million USD | 37.773% |
| Cibus, Inc. | 320.3 Million USD | 95.762% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 91.504% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 91.544% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | 68.428% |
| Kodiak Sciences Inc. | 277.32 Million USD | 95.105% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 95.397% |
| Annexon, Inc. | 143.72 Million USD | 90.554% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 89.36% |
| Assembly Biosciences, Inc. | 22.9 Million USD | 40.739% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | 60.735% |
| Moderna, Inc. | 6.39 Billion USD | 99.788% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 84.723% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 98.259% |
| Vor Biopharma Inc. | 126.03 Million USD | 89.228% |
| Eyenovia, Inc. | 25.4 Million USD | 46.565% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | 36.164% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 90.325% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 90.527% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 92.512% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -144.085% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 98.2% |
| Immunocore Holdings plc | 308.04 Million USD | 95.593% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 90.991% |
| Galectin Therapeutics Inc. | 38.07 Million USD | 64.341% |
| Alkermes plc | 996.24 Million USD | 98.637% |
| Arcellx, Inc. | 200.19 Million USD | 93.219% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 83.371% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 94.624% |
| Sagimet Biosciences Inc. | 32.74 Million USD | 58.534% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -36.346% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -87.01% |
| Moolec Science SA | 52.75 Million USD | 74.264% |
| Biomea Fusion, Inc. | 126.13 Million USD | 89.237% |
| RenovoRx, Inc. | 11.39 Million USD | -19.13% |
| Geron Corporation | 70.44 Million USD | 80.727% |
| Mereo BioPharma Group plc | 35.84 Million USD | 62.123% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | 80.769% |
| Royalty Pharma plc | 862.4 Million USD | 98.426% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 85.569% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -45.542% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 66.635% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | 40.005% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 93.467% |
| Humacyte, Inc. | 23.49 Million USD | 42.222% |
| Structure Therapeutics Inc. | 102.77 Million USD | 86.791% |
| NLS Pharmaceutics AG | 11.8 Million USD | -14.982% |
| Genelux Corporation | 24.33 Million USD | 44.212% |
| ESSA Pharma Inc. | 32.13 Million USD | 57.752% |
| aTyr Pharma, Inc. | 12.97 Million USD | -4.6% |
| Notable Labs, Ltd. | 14.77 Million USD | 8.084% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -36.612% |
| Mustang Bio, Inc. | 48.5 Million USD | 72.009% |
| Immunovant, Inc. | 282.7 Million USD | 95.198% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -497.018% |
| Vericel Corporation | 142.04 Million USD | 90.442% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 95.464% |
| Akari Therapeutics, Plc | 16.8 Million USD | 19.219% |
| Acasti Pharma Inc. | 11.3 Million USD | -20.131% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | 40.771% |
| Vaxcyte, Inc. | 468.04 Million USD | 97.099% |
| Orgenesis Inc. | 45.75 Million USD | 70.33% |
| Spruce Biosciences, Inc. | 62.08 Million USD | 78.132% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | 14.541% |
| GH Research PLC | 41.22 Million USD | 67.066% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | 53.438% |
| PepGen Inc. | 84.76 Million USD | 83.984% |
| Moleculin Biotech, Inc. | 29.63 Million USD | 54.183% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 86.909% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | 58.516% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -166.707% |
| Silo Pharma, Inc. | 3.92 Million USD | -246.163% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -244.39% |
| Belite Bio, Inc | 31.66 Million USD | 57.13% |
| Pharming Group N.V. | 225.49 Million USD | 93.979% |
| XOMA Corporation | 46.46 Million USD | 70.781% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 83.654% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 44.147% |
| Bionomics Limited | 17.89 Billion USD | 99.924% |
| Xencor, Inc. | 306.97 Million USD | 95.578% |
| Replimune Group, Inc. | 234.77 Million USD | 94.217% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 83.483% |
| Cassava Sciences, Inc. | 105.95 Million USD | 87.187% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 92.922% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -85.716% |
| Turnstone Biologics Corp. | 78.33 Million USD | 82.67% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 22.232% |
| GeoVax Labs, Inc. | 6.02 Million USD | -125.434% |
| MEI Pharma, Inc. | 34.78 Million USD | 60.972% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 87.066% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -87.01% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 14.309% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | 53.815% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | 17.621% |
| scPharmaceuticals Inc. | 65.17 Million USD | 79.171% |
| HilleVax, Inc. | 133.34 Million USD | 89.819% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 86.692% |
| Tharimmune, Inc. | 9.45 Million USD | -43.582% |
| Genprex, Inc. | 31.06 Million USD | 56.292% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | 4.462% |
| Immunic, Inc. | 99.22 Million USD | 86.318% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | 56.733% |
| Aptorum Group Limited | 10.56 Thousand USD | -128387.602% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | 67.195% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | 4.462% |
| OKYO Pharma Limited | 8243.57 USD | -164585.931% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -166.589% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | 49.759% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -447.058% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 96.825% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -105189.282% |
| bluebird bio, Inc. | 240.23 Million USD | 94.349% |
| DBV Technologies S.A. | 92.16 Million USD | 85.269% |
| Compugen Ltd. | 43.97 Million USD | 69.125% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -199.891% |
| Peak Bio, Inc. | 1249.13 USD | -1086736.438% |
| Vincerx Pharma, Inc. | 42.6 Million USD | 68.138% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | 5.499% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | 63.371% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | 74.896% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 81.684% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | 79.646% |
| Benitec Biopharma Inc. | 22.38 Million USD | 39.344% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 94.418% |
| Adicet Bio, Inc. | 152.03 Million USD | 91.071% |
| Prime Medicine, Inc. | 186.63 Million USD | 92.726% |
| Aditxt, Inc. | 25.95 Million USD | 47.686% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 96.432% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -85.716% |
| Quantum-Si incorporated | 111.65 Million USD | 87.842% |
| GlycoMimetics, Inc. | 39.28 Million USD | 65.443% |
| PolyPid Ltd. | 21.04 Million USD | 35.491% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | 16.589% |
| Invivyd, Inc. | 205.75 Million USD | 93.402% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -44.757% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 89.578% |
| CorMedix Inc. | 48.95 Million USD | 72.27% |
| Instil Bio, Inc. | 85.78 Million USD | 84.174% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 96.144% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | 59.749% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 58.342% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 81.96% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 138.049% |
| AbCellera Biologics Inc. | 275.23 Million USD | 95.067% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 89.984% |
| Surrozen, Inc. | 18.55 Million USD | 26.814% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 83.252% |
| Verona Pharma plc | 67.15 Million USD | 79.783% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 86.763% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 98.232% |
| Evaxion Biotech A/S | 22.27 Million USD | 39.039% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 94.22% |
| Shattuck Labs, Inc. | 93.61 Million USD | 85.498% |
| AlloVir, Inc. | 180.93 Million USD | 92.497% |
| BioVie Inc. | 31.95 Million USD | 57.509% |
| Codexis, Inc. | 66.51 Million USD | 79.59% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | 64.15% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -101.762% |
| Agenus Inc. | 78.18 Million USD | 82.636% |
| Virax Biolabs Group Limited | 6.54 Million USD | -107.36% |
| Lantern Pharma Inc. | 17.87 Million USD | 24.061% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 94.671% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 59.887% |
| Immix Biopharma, Inc. | 16.14 Million USD | 15.892% |
| Celcuity Inc. | 66.23 Million USD | 79.502% |
| Cardiff Oncology, Inc. | 45.9 Million USD | 70.423% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | 77.794% |
| IN8bio, Inc. | 30.33 Million USD | 55.249% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | 6.63% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | 59.98% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 92.147% |
| Liquidia Corporation | 87.98 Million USD | 84.57% |
| Quantum-Si incorporated | 111.65 Million USD | 87.842% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | 15.04% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | 70.831% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | 56.006% |
| United Therapeutics Corporation | 885.1 Million USD | 98.466% |
| Solid Biosciences Inc. | 104.31 Million USD | 86.986% |
| Immuneering Corporation | 58.41 Million USD | 76.759% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 138.049% |
| uniQure N.V. | 285.08 Million USD | 95.238% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 82.844% |
| Enveric Biosciences, Inc. | 16.44 Million USD | 17.463% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 93.01% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | 76.081% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 83.058% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -1096.566% |
| Cue Biopharma, Inc. | 19.54 Million USD | 30.529% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | 40.708% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | 79.902% |
| Zura Bio Limited | 62.63 Million USD | 78.326% |
| Forte Biosciences, Inc. | 32.47 Million USD | 58.198% |
| Elevation Oncology, Inc. | 45.44 Million USD | 70.127% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -144.085% |
| Immunome, Inc. | 122.82 Million USD | 88.946% |
| Compass Therapeutics, Inc. | 48.47 Million USD | 71.993% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | 47.553% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 89.758% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | 80.799% |
| Altimmune, Inc. | 30.55 Million USD | 55.57% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | 78.138% |
| Rallybio Corporation | 78.93 Million USD | 82.8% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -58.895% |
| Dianthus Therapeutics, Inc. | 51 Million USD | 73.38% |
| Moolec Science SA | 52.75 Million USD | 74.264% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -63.394% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -1674.641% |
| Tourmaline Bio, Inc. | 45.4 Million USD | 70.103% |
| NeurAxis, Inc. | 8.82 Million USD | -53.902% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 92.1% |
| Lumos Pharma, Inc. | 38.66 Million USD | 64.888% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | 47.553% |
| 180 Life Sciences Corp. | 13.47 Million USD | -0.731% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | 52.437% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | 48.775% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -362.873% |
| Nutriband Inc. | 5.73 Million USD | -136.762% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | 75.606% |
| argenx SE | 1.53 Billion USD | 99.115% |
| Neurogene Inc. | 55.58 Million USD | 75.575% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 94.537% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -60.644% |
| CervoMed Inc. | 14.95 Million USD | 9.238% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 85.962% |
| Sesen Bio, Inc. | 78.38 Million USD | 82.679% |
| AnaptysBio, Inc. | 181.56 Million USD | 92.523% |
| Design Therapeutics, Inc. | 78.19 Million USD | 82.637% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 84.403% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -7.874% |
| Achilles Therapeutics plc | 75.25 Million USD | 81.96% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -31.998% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 87.745% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | 73.317% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | 79.461% |
| MoonLake Immunotherapeutics | 54.12 Million USD | 74.916% |
| Palisade Bio, Inc. | 13.32 Million USD | -1.922% |
| Beam Therapeutics Inc. | 554.19 Million USD | 97.55% |
| AEON Biopharma, Inc. | 48.42 Million USD | 71.967% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 83.747% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -7.858% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 96.99% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 84.553% |
| Athira Pharma, Inc. | 125.46 Million USD | 89.18% |
| Vaccinex, Inc. | 23.45 Million USD | 42.119% |
| HCW Biologics Inc. | 21.02 Million USD | 35.437% |
| XOMA Corporation | 46.46 Million USD | 70.781% |
| Nektar Therapeutics | 190.9 Million USD | 92.889% |
| Arvinas, Inc. | 480 Million USD | 97.172% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -497.018% |
| Merus N.V. | 200.49 Million USD | 93.229% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 86.865% |
| Quince Therapeutics, Inc. | 34.62 Million USD | 60.786% |
| Rezolute, Inc. | 70.38 Million USD | 80.712% |
| Clene Inc. | 41.07 Million USD | 66.947% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | 17.111% |
| BeyondSpring Inc. | 24.86 Million USD | 45.401% |
| Synlogic, Inc. | 58.53 Million USD | 76.806% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | 24.123% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -202.226% |
| Peak Bio, Inc. | 1249.13 USD | -1086736.438% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | 77.54% |
| Krystal Biotech, Inc. | 160.42 Million USD | 91.538% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 94.984% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 96.099% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -529.47% |
| MannKind Corporation | 125.59 Million USD | 89.191% |
| Ikena Oncology, Inc. | 84.57 Million USD | 83.948% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -40.728% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 84.848% |
| Gossamer Bio, Inc. | 183.75 Million USD | 92.612% |
| CohBar, Inc. | 12.38 Million USD | -9.587% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | 73.236% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 50.779% |
| Legend Biotech Corporation | 583.14 Million USD | 97.672% |
| Mural Oncology plc | 192.07 Million USD | 92.932% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 79.782% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 15.913% |
| Disc Medicine, Inc. | 91.12 Million USD | 85.102% |
| Champions Oncology, Inc. | 28.11 Million USD | 51.704% |
| REGENXBIO Inc. | 321.15 Million USD | 95.773% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -153.225% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 75.651% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | 65.155% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 88.128% |
| Vaxart, Inc. | 90.72 Million USD | 85.036% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -59.343% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | 68.276% |
| Cellectis S.A. | 97.32 Million USD | 86.05% |
| Longeveron Inc. | 21.25 Million USD | 36.113% |
| Repare Therapeutics Inc. | 167.35 Million USD | 91.888% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 99.002% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 82.053% |
| Revolution Medicines, Inc. | 498.76 Million USD | 97.278% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -104.089% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | 69.113% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 81.799% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | 80.504% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -22.749% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.716% |
| Denali Therapeutics Inc. | 527.23 Million USD | 97.425% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -56.827% |
| Veru Inc. | 101.34 Million USD | 86.605% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | 42.0% |
| Cingulate Inc. | 22.75 Million USD | 40.349% |
| Passage Bio, Inc. | 108.38 Million USD | 87.475% |
| Context Therapeutics Inc. | 25.07 Million USD | 45.853% |
| Exicure, Inc. | 14.07 Million USD | 3.552% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 93.412% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | 68.647% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 97.278% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -47.93% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 94.623% |
| Nuvalent, Inc. | 149.49 Million USD | 90.919% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -68.293% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 86.902% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | 36.706% |
| OmniAb, Inc. | 83.89 Million USD | 83.818% |
| Anew Medical, Inc. | 1.3 Million USD | -943.633% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | 58.564% |
| Lipocine Inc. | 15.08 Million USD | 9.974% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | 80.185% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 82.172% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 66.325% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 88.179% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | 39.35% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 97.956% |
| Ocugen, Inc. | 71.56 Million USD | 81.03% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 85.537% |
| Q32 Bio Inc. | 92.68 Million USD | 85.352% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | 35.884% |
| Alumis Inc. Common Stock | 158.17 Million USD | 91.417% |
| Equillium, Inc. | 50.6 Million USD | 73.173% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | 78.246% |
| Coya Therapeutics, Inc. | 13.9 Million USD | 2.37% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | 28.036% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 71.085% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 87.484% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -9.548% |
| Dominari Holdings Inc. | 23.83 Million USD | 43.042% |
| Edesa Biotech, Inc. | 9.22 Million USD | -47.201% |
| vTv Therapeutics Inc. | 11.9 Million USD | -14.017% |
| Bio-Techne Corporation | 563.03 Million USD | 97.589% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 96.679% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 94.949% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 89.737% |
| Candel Therapeutics, Inc. | 14.41 Million USD | 5.794% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 91.707% |
| Nkarta, Inc. | 131.65 Million USD | 89.688% |
| BioCardia, Inc. | 12.12 Million USD | -12.004% |
| Iterum Therapeutics plc | 47.46 Million USD | 71.4% |